Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel
B Jin, HC Ni, W Shen, J Li, HM Shi, Y Li - Molecular biology reports, 2011 - Springer
Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
JB Jin Bo, NHC Ni HuanChun, SW Shen Wei… - 2011 - cabidigitallibrary.org
Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel
B Jin, H Ni, W Shen, J Li, H Shi… - Molecular Biology …, 2011 - search.proquest.com
Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel
B Jin, HC Ni, W Shen, J Li… - Molecular biology …, 2011 - pubmed.ncbi.nlm.nih.gov
Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel
B Jin, HC Ni, W Shen, J Li, HM Shi, Y Li - Molecular Biology Reports, 2011 - infona.pl
Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
B Jin, HC Ni, W Shen, J Li, HM Shi, Y Li - Molecular Biology Reports, 2010 - europepmc.org
Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
[PDF][PDF] Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel
B Jin, HC Ni, W Shen, J Li, HM Shi, Y Li - Mol Biol Rep, 2011 - researchgate.net
Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
B Jin, HC Ni, W Shen, J Li, HM Shi… - Molecular Biology …, 2011 - search.ebscohost.com
Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …